Custom-Made cancer vaccines enter human testing
NCT ID NCT05741242
First seen Jan 16, 2026 · Last updated Jun 20, 2026 · Updated 19 times
Summary
This trial tests a personalized vaccine made from unique proteins in a patient's tumor. The goal is to train the immune system to recognize and attack cancer cells. It is open to people with solid tumors that have spread or are locally advanced. The study will check if the vaccine is safe and can help stop the cancer from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anna Gattani MD PC
New York, New York, 10028, United States
-
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
Precision NextGen Oncology & Research Center
Beverly Hills, California, 90212, United States
-
Quest Clinical Research
San Francisco, California, 94115, United States
-
St. Louis Cancer Care
Bridgeton, Missouri, 63044, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized synthetic long peptide vaccine
What this could lead to
If this works, it could point toward a new way to train the immune system to fight cancer, potentially slowing tumor growth or preventing recurrence.
What could go wrong
This is an early-phase trial (1b/2) with a small number of participants, so results may not apply broadly. The vaccine is personalized, making it complex and costly, and it may not work for all tumor types.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.